Neurocrine Biosciences, Inc.
General ticker "NBIX" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $12.8B (TTM average)
Neurocrine Biosciences, Inc. follows the US Stock Market performance with the rate: 65.0%.
Estimated limits based on current volatility of 1.2%: low 130.31$, high 133.71$
Factors to consider:
- Total employees count: 1800 (+28.6%) as of 2024
- Top business risk factors: Product commercialization failure, Market competition, Reimbursement risks, Intellectual property risks, Customer concentration
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [131.07$, 187.49$]
- 2026-12-31 to 2027-12-31 estimated range: [140.68$, 199.92$]
Financial Metrics affecting the NBIX estimates:
- Negative: with PPE of 28.5 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 21.64 > 18.38
- Positive: Inventory ratio change, % of -0.02 <= 0
- Positive: Return on assets ratio (scaled to [-100,100]) of 9.37 > 6.11
- Positive: Shareholder equity ratio, % of 70.24 > 64.29
- Negative: Investing cash flow per share per price, % of -1.84 <= -0.63
- Positive: 0.01 < Operating cash flow per share per price, % of 5.46
Short-term NBIX quotes
Long-term NBIX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1,887.10MM | $2,355.30MM | $2,860.50MM |
| Operating Expenses | $1,636.20MM | $1,784.80MM | $2,241.40MM |
| Operating Income | $250.90MM | $570.50MM | $619.10MM |
| Non-Operating Income | $81.20MM | $-84.50MM | $86.30MM |
| Interest Expense | $4.60MM | $126.60MM | $0.00MM |
| R&D Expense | $565.00MM | $731.10MM | $1,015.70MM |
| Income(Loss) | $332.10MM | $486.00MM | $705.40MM |
| Taxes | $82.40MM | $144.70MM | $226.80MM |
| Profit(Loss)* | $249.70MM | $341.30MM | $478.60MM |
| Stockholders Equity | $2,232.00MM | $2,589.70MM | $3,253.10MM |
| Inventory | $38.30MM | $57.40MM | $69.00MM |
| Assets | $3,251.40MM | $3,718.70MM | $4,631.50MM |
| Operating Cash Flow | $389.90MM | $595.40MM | $782.70MM |
| Capital expenditure | $28.30MM | $38.20MM | $34.00MM |
| Investing Cash Flow | $-467.10MM | $-126.80MM | $-264.40MM |
| Financing Cash Flow | $65.30MM | $-486.70MM | $-38.30MM |
| Earnings Per Share** | $2.56 | $3.40 | $4.81 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.